Company Overview
Seres Therapeutics, Inc. operates as a clinical-stage biotechnology company dedicated to developing biotherapeutics designed to treat serious diseases. The firm's primary focus is on creating SER-155, an investigational oral live biotherapeutic aimed at decolonizing gastrointestinal pathogens, enhancing GI epithelial barrier integrity, and regulating immune response to prevent bacterial infections. This entity functions within the healthcare sector and specifically the biotechnology industry, where innovation in therapeutic modalities often precedes commercial product launches. The company maintains a market capitalization of $86.28M and reports annual revenue of $789,000, while employing 66 individuals. These valuation and revenue figures indicate a small-cap position typical of early-stage clinical entities that are currently generating minimal sales but are investing heavily in research and development to advance their pipeline toward future commercialization.
Financial Health
The company reports a trailing twelve-month revenue of $789,000, a net income of $5.70M, and an EBITDA of $-89,838,000. The significant disparity between the low revenue figure and the positive net income, juxtaposed against a massive negative EBITDA, reveals a highly leveraged cost structure where interest expenses on substantial debt are likely offsetting operational losses to produce a reported profit on paper. The company reports a free cash flow of $-54,955,876, which indicates a severe lack of financial flexibility as the firm must rely entirely on external capital sources to fund its operations and development programs. Analysis of the margin profile shows a gross margin of 0.0%, an operating margin of -4424.0%, and a profit margin of 721.9%. The negative gross and operating margins suggest that costs of goods sold and operating expenses far exceed revenue, while the anomalous positive profit margin is driven by non-operating income or interest income relative to the small revenue base. The firm holds $45.77M in cash against $82.97M in debt, resulting in a debt-to-equity ratio of 187.63, which signifies a highly leveraged balance sheet rather than a conservative one. Despite the heavy debt load, the current ratio stands at 2.56, indicating that the company possesses sufficient current assets to cover its short-term liabilities without immediate distress. Return on Equity is calculated at 19.6% while return on assets is -42.3%, revealing that management is generating returns on shareholder equity through financial leverage, but the asset base is generating negative returns, highlighting the risks associated with the company's capital structure.
Valuation Assessment
The valuation metrics present a complex picture, with a trailing P/E ratio of 14.06 and a forward P/E of -0.98. The divergence between these two figures implies that while historical earnings suggest a positive multiple, the market expects earnings to deteriorate or turn negative in the near future due to the projected loss trajectory. The price-to-book ratio is 1.95, indicating that the market values the company at nearly double its book value, a premium that may reflect potential in the clinical pipeline or the quality of assets despite current cash burn. Alternative valuation measures include a price-to-sales ratio of 109.35 and an EV/EBITDA of -1.37, suggesting that traditional revenue multiples are being used as the primary valuation anchor since earnings multiples are skewed by negative EBITDA. The stock has traded between a 52-week low of $6.53 and a 52-week high of $29.98, providing the range within which the current price must be evaluated by investors. The beta value of 0.29 indicates that the stock's price volatility is significantly lower than the broader market, suggesting lower sensitivity to general market fluctuations compared to large-cap peers.
Growth & Income
Revenue growth year-over-year is listed as N/A, and earnings growth year-over-year is also N/A due to the company's small revenue base and current stage of development. Because the growth rates are not applicable in the traditional sense for a clinical-stage firm, the comparison between earnings and revenue growth is not standard, but the current profit margin suggests earnings are currently supported by non-operating factors rather than operational scale. The company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This absence of dividends confirms that the firm reinvests all available earnings and cash flow into research and development activities rather than distributing income to shareholders. The overall growth and income profile is characterized by zero dividend income and undefined historical growth rates, reflecting the strategic focus on capitalizing the business through future product approvals rather than current shareholder distributions.